bioRxiv Science⌕ Search

Biology subjects

Gonzalez Hernandez, F.

Publications and source records attributed to Gonzalez Hernandez, F..

2 recordsLinked to original sources

Generative Language Modeling for Antibody CDR Grafting and Alignment-driven De Novo Design

Antibodies recognise their targets through hypervariable complementarity-determining regions (CDRs), which are interleaved with conserved frameworks in sequence space, making de novo CDR design an infilling problem. Autoregressive models generate residues left-to-right, which precludes full framework context during CDR generation and conflates framework and CDR likelihoods, leaving no natural prompt-response interface for feedback to steer generation. We present GenCDR, a family of LLaMa-based autoregressive language models that read all frameworks as a conditioning prompt and generate all CDRs jointly as a variable-length response, making CDR likelihoods a clean, separable target for reward attribution. The family comprises IgGenCDR, p-IgGenCDR, and NanoGenCDR, trained on unpaired, paired, and nanobody chains, respectively. GenCDR achieves the highest CDR recovery among autoregressive models and produces natural, diverse, human-like CDRs whose likelihoods correlate with fitness and developability assays. The prompt-response boundary also enables principled alignment: reward signals for binding affinity, expression, or developability can be composed to steer CDR generation. Over four rounds of alignment against antibody-antigen co-folding and developability objectives, we find that NanoGenCDR, which uses no explicit antigen encoding, can reach in silico structural interface metrics competitive with those of a structure-conditioned diffusion pipeline at roughly half the sampling budget, with more natural, developable designs. The same interface can be extended to integrate experimental feedback, opening a path to closed-loop antibody de novo design.

synthetic biology↗

Benchmarking Generative Models for Antibody Design

Generative models trained on antibody sequences and structures have shown great potential in advancing machine learning-assisted antibody engineering and drug discovery. Current state-of-the-art models are primarily evaluated using two categories of in silico metrics: sequence-based metrics, such as amino acid recovery (AAR), and structure-based metrics, including root-mean-square deviation (RMSD), predicted alignment error (pAE), and interface predicted template modeling (ipTM). While metrics such as pAE and ipTM have been shown to be useful filters for experimental success, there is no evidence that they are suitable for ranking, particularly for antibody sequence designs. Furthermore, no reliable sequence-based metric for ranking has been established. In this work, using real-world experimental data from fourteen diverse datasets, we extensively benchmark a range of generative models, including LLM-style, diffusion-based, and graph-based models. We show that log-likelihood scores from these generative models have promising correlation with experimentally measured binding affinities, suggesting that log-likelihood can potentially serve as a reliable metric for ranking antibody sequence designs. Additionally, we scale up one of the diffusion-based models by training it on a large and diverse synthetic dataset, significantly enhancing its ability to rank antibodies based on their binding affinities. We also evaluate non-log-likelihood-based metrics on ten datasets and find that, while they are less consistent for ranking, they provide complementary information. Structure-, energy-, and sequence-based scores appear to be orthogonal and may be used together to increase the likelihood of experimental success. Our implementation is available at: https://github.com/AstraZeneca/DiffAbXL

bioinformatics↗